Review

Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.

Simone Lista L. Filippi Enzo Emanuele S. López-Ortiz Giusy Ylenia Cisale P. Minoretti F. Garaci Alejandro Santos-Lozano

Sep 2026 · Molecular Diagnosis & Therapy · 0 citations · 121 references

Medicine

TL;DR

A narrative review of the principal Aβ positron emission tomography radioligands and their methodological framework, including visual reads, the standardized uptake value ratio, and the Centiloid scale, which harmonized quantitative output across tracers, scanners, and protocols and may enable cross-site comparison in multicenter studies and disease-modifying trials.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Open access Jul 2026

From amyloid PET to plasma biomarkers: A multimodal imaging framework for early diagnosis and staging of Alzheimer's disease

Alzheimer's disease (AD) is biologically defined by amyloid beta and tau pathology. Available biomarkers enable early diagnosis but differ in targets, accessibility, and utility. This review synthesizes evidence for plasma biomarkers, magnetic resonance imaging (MRI), and positron emission tomography (PET) to develop a...

Jia-Yu Liu, Chou Xu, Yu-Xin Wang et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.

Arthur C. Macedo, Lydia Trudel, S. A. Hosseini et al. · EBioMedicine · 1 citation

Sep 2026

Clinic-based real-world analysis of amyloid PET positivity and MRI markers across subjective cognitive decline, mild cognitive impairment, and early Alzheimer's disease.

BackgroundAlzheimer's disease (AD) is increasingly defined biologically. Amyloid positron emission tomography (PET) is a validated biomarker; however, evidence from truly consecutive, real-world memory-clinic cohorts spanning subjective cognitive decline (SCD), mild cognitive impairment (MCI), and early AD remains limi...

Heii Arai, Satoko Aiba, Hideo Yamamoto et al. · Journal of Alzheimer's Disea... · 0 citations

Open access Sep 2026

Dynamic [18F]PI-2620 recording facilitates prediction of β-amyloid positivity and simultaneous staging of tau and neurodegeneration

Dynamic [18F]PI-2620 PET imaging facilitates assessment of the β-amyloid status and regional staging of tau and neurodegeneration during a single acquisition, and may reduce radiation exposure, streamline diagnostic workflows, and facilitate personalized disease profiling.

Johannes S. Gnörich, J. Kusche-Palenga, Agnes Kling et al. · Molecular Neurodegeneration · 0 citations

Sep 2026

Quantitative Assessment of Cerebrospinal Fluid-Vascular Association in Alzheimer's Disease Using Phase-Contrast and 4D-Flow Magnetic Resonance Imaging.

Altered CSF-vascular association was observed in Alzheimer's disease, suggesting possible glymphatic involvement, and the integration of CSF and vascular flow metrics provides a promising biomarker framework for early AD detection and monitoring.

Meng-Ying Lu, Yu-Shan Zheng, Ting-Ting Chen et al. · Journal of Visualized Experi... · 0 citations

Open access Sep 2026

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

L. Gualco, N. Montobbio, M. Losa et al. · European Radiology Experimen... · 0 citations